Journal: Hereditas

Article Title: Investigating the effect of tenuigenin on LPS-induced HPMEC dysfunction by inhibiting SRC activation based on network pharmacology and molecular docking

doi: 10.1186/s41065-025-00574-6

Figure Lengend Snippet: SRC is the target of Tenuigenin in adult pneumonia. ( A ) The TOP 10 hub genes of Tenuigenin in adult pneumonia were screened according to the MNC, MCC, and Degree values of the CytoHubba. ( B ) The image showed the 3D structure of SRC. ( C ) The 3D image showed the optimal conformation of Tenuigenin and SRC (affinity: -9.6 kcal/mol) visualized by the PyMOL software. ( D ) The 3D combination image of Tenuigenin and SRC was visualized by the PyMOL software. ( E ) The 2D combination image of Tenuigenin and SRC was visualized by the Discovery Studio 4.5 software. ( F ) Western blot was applied to examine the protein expression of SRC and p-SRC in HPMECs co-treated with Tenuigenin (0, 1, and 4 µg/mL) and LPS (1 µg/mL). All experiments were repeated three times. *** P < 0.001

Article Snippet: Cells were treated with Tenuigenin (0.5, 1, 2, 4, 8, and 16 μg/mL; MedChemExpress (MCE), Monmouth Junction, New Jersey, The United States of America (USA)), LPS (1 μg/mL, MCE), and/or SRC kinase inhibitor AZM475271 (20 μM, MCE) alone or together for 12 h as needed.

Techniques: Software, Western Blot, Expressing

Journal: Hereditas

Article Title: Investigating the effect of tenuigenin on LPS-induced HPMEC dysfunction by inhibiting SRC activation based on network pharmacology and molecular docking

doi: 10.1186/s41065-025-00574-6

Figure Lengend Snippet: Tenuigenin weakens LPS-induced HPMEC injury and dysfunction through the SRC pathway. The HPMECs were treated with LPS, Tenuigenin, and AZM475271. ( A ) Western blot was used to examine the protein expression of SRC and p-SRC. ( B ) EdU staining was applied to measure the EdU-positive cells. ( C ) The migrated cells were determined by transwell assay. ( D ) The angiogenesis was examined by tube formation assay. ( E ) Flow cytometry was employed to detect apoptosis. ( F ) The calcium ions levels were evaluated by the Fluo-4 Calcium Assay Kit. ( G ) The ROS levels were estimated by flow cytometry. ( H ) The TER was measured by the TER method. ( I ) The cell permeability was determined by transwell assay. ( J ) Western blot was employed to examine the protein expression of VE-cadherin and ZO-1. All experiments were repeated three times. * P < 0.05, ** P < 0.01, *** P < 0.001

Article Snippet: Cells were treated with Tenuigenin (0.5, 1, 2, 4, 8, and 16 μg/mL; MedChemExpress (MCE), Monmouth Junction, New Jersey, The United States of America (USA)), LPS (1 μg/mL, MCE), and/or SRC kinase inhibitor AZM475271 (20 μM, MCE) alone or together for 12 h as needed.

Techniques: Western Blot, Expressing, Staining, Transwell Assay, Tube Formation Assay, Flow Cytometry, Calcium Assay, Permeability

Journal: Oncotarget

Article Title: IL-17E synergizes with EGF and confers in vitro resistance to EGFR-targeted therapies in TNBC cells

doi: 10.18632/oncotarget.10804

Figure Lengend Snippet: IJG-1731, BT20, and MDA-MB468 cells were treated with the Src specific inhibitor AZM475271 (10 μM) ( A ), Iressa (0.25 μM) ( B ), or control DMSO and then stimulated with IL-17E (10 ng/ml), EGF (10 ng/ml) or with medium alone. EGFR and Src phosphorylation was then assessed by western blotting (left panel). Loading controls were determined by re-blotting the membranes with an anti-EGFR antibody. Data are representative of at least 2 independent experiments. In the right panel, densitometric quantification of Y416 Src and Y1086 EGFR, as shown in the representative blots, is expressed as the ratios of pY416 Src to EGFR and pY1086 EGFR to EGFR, as indicated.

Article Snippet: Iressa (Gefitinib) and the Src inhibitor AZM475271 were obtained from Tocris Bioscience (R&D systems).

Techniques: Control, Phospho-proteomics, Western Blot